CYP3A4 and peripheral arterial disease: Moreover, it is worth mentioning that drug interaction and potent inhibitors of cytochrome P450 (CYP) 3A4 inhibitors (atorvastatin is metabolized by CYP3A4) can significantly increase statin concentrations (Hirota et al., 2020), and clinical research on atorvastatin tends to apply high dose (Pedersen et al., 2005) since high-dose atorvastatin is superior in preventing peripheral arterial disease (Stoekenbroek et al., 2015).